| Acino CMO specific technology capabilities Acino International Drug Product : Small Molecules For many decades, Acino has been mastering the manufacturing of pharmaceuticals and gained in-depth knowledge in the processing of oral solid dosage forms (granulate, pellets, tablets & capsules). This poster provides an overview of the specific Acino CMO technology capabilities for oral solid dosage forms and services. Keywords: Acino CMO specific technology capabilities for OSD Alina Simonenko [email protected] View PDF | Application of MVDA, Raman Spectroscopy and Process Control to enhance bioprocess understanding APC Ltd. Drug Substance : Biologics Chinese Hamster Ovary cells are the most widely-used platform for the production of monoclonal antibodies (mAbs) by the biopharmaceutical sector. CHO cell mAb manufacturing processes require refinement to ensure that the highest product yield is achieved while ensuring quality. The use of Process Analytical Technology (PAT), such as Raman spectroscopy, enables in-depth interrogation of cell culture operations in order to define optimal feeding and control strategies. Keywords: MVDA, Raman Spectroscopy, Process Control, Process Development David Crowley [email protected] View PDF |
| Innovation in Flow Chemistry for Accelerating the Critical Path to First-in-Human Trials Arcinova Drug Substance : Small Molecules There is an urgent market need for an integrated drug substance / drug product offering using one site and with an intensive technology focus. The new Arcinova model ensures secure delivery of technically complex projects with a focus on velocity and scalability. Rapid delivery of materials to Biotech clients is a key differentiator and aligns with the Biotech fundraising model, which is highly focused on clinical deliverables and payment milestones. Keywords: Innovation, Flow Technology, Drug Substance, Drug Product, Scalability, Biotech Paul Quigley [email protected] View PDF | Ardena services Ardena Discovery : Small Molecules Ardena offers an integrated, flexible service encompassing drug substance production, dosage form manufacture, clinical logistics, bioanalysis and dossier development. We are also at the leading edge of nanomedicine development. Our precision particle engineering and characterisation technologies are the key to accessing this fast evolving, competitive market. Keywords: Drug Substance, Drug Product, Solid State Research, API, Nanomedicines, Clinical Supply, Bioanlysis, Regulatory Dossier Development Joren De Koning [email protected] View PDF |
| Continuous Production of Anhydrous tert-Butyl Hydroperoxide in Nonane Using Membrane Pervaporation and Its Application in Flow
Oxidation of a γ-Butyrolactam Asymchem Laboratories (Tianjin) Co Ltd Drug Substance : Small Molecules Anhydrous tert-butyl hydroperoxide (TBHP) is a powerful oxidizing agent in many chemical transformations. Despite its versatility, the use of anhydrous TBHP has been greatly limited because of safety concerns, particularly on a production scale. We describe a membrane pervaporation method that allows the production of anhydrous TBHP solution in continuous manner. The system consists of membrane modules in series that are made of perfluorinated polymer, allowing it to remove water efficiently. Keywords: Flow chemistry, Membrane pervaporation, Oxidation, Continuous process, Continuous extraction, Diastereoselective synthesis, Continuous concentration, End-to-end, Power Of Flow Jordi Robinson [email protected] View PDF | Biotech Outsourcing Strategies Events Poster Bio2Business Ltd Discovery : Small Molecules BOS Events Overview Keywords: Conference, Exhibition, Outsourcing, Manufacturing, Discovery, Partnering Richard Collins [email protected] |
| Locating and understanding hydrated forms of an API Cambrex Drug Substance : Small Molecules Facile hydrate formation can drastically alter the processability, stability and aqueous solubility of a given API. Cambrex Edinburgh was able to fully characterize and develop a reliable method for avoiding the hemi-hydrated form of an API that was discovered during a polymorph screening project. Keywords: View PDF | Capture Compound Mass Spectrometry®: on- and off-target deconvolution Charles River Discovery : Small Molecules Capture Compound Mass Spectrometry(CCMS) is an unbiased, proteome-wide approach for the identification of specific-binding protein targets for small molecules and peptides. The technology combines medicinal chemistry and in vitro pharmacology, coupled to high resolution proteomics mass spectrometry to isolate and identify target proteins that are responsible for an observed biological response. This technology can be used in a variety of contexts from target de-convolution and drug re-purposing. Keywords: target, deconvolution, toxicity Tammy Ladduwahetty [email protected] View PDF |
| INOFEA Poster BOS 2019 INOFEA AG Discovery : Other Keywords: empowered enzymes, bioanalysis, bioconjugation, biocatalysis Dr. Yves Dudal [email protected] View PDF | This is not just fill finish: insight from a C(D)MO perspective Legacy Pharmaceuticals Switzerland GmbH Drug Product : Biologics After a long and expensive process to develop DS, biotech companies want to quickly move to First-in-Human. The added value of Fill Finish is often regarded as a simple development step, but it is actually extremely complex in nature. Not enough time for Fill Finish partners selection and technology transfer is usually planned, as well as for primary packaging selection. The establishment of a strong Fill Finish partners network early in the process could save time and money in DP developments. Keywords: sterile aseptic fill finish contract manufacturing Carole Delauney [email protected] View PDF |
| Development of an early wound model in human ex vivo skin explant as a preclinical model of wound healing MedPharm Discovery : Small Molecules This assay has the potential to be used as an early screening tool for drug selection and topical formulation optimisation for NCE and generic medicine development for the advanced healing of wounded skin. Whether targeting keratinocyte proliferation and differentiation, modulation of inflammatory response, or collagen and fibroblast remodeling, this model has the potential for proof of concept research in the dermatological advancement of topical wound therapies. Keywords: Wound Healing, Model, Ex Vivo, Skin, Pre-Clinical Daniel Morland [email protected] View PDF | The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel Metrion Biosciences Discovery : Small Molecules Ion channels represent 15-20% of historic drug approvals but are notoriously complex targets and require specialised screening technology such as automated patch clamp (APC) electrophysiology. We outline a situation where a pharma company turns to a specialist CRO to fill their knowledge gap. During the collaboration, we developed potent and selective Kv1.3 modulators with nM efficacy against human T-cells and potential to treat auto-immune disease. Keywords: small molecules; ion channels; potassium channels; drug discovery; auto-immune disease Sophie Rose [email protected] View PDF |
| CESS for the Production of Nanoparticles Nanoform Finland Drug Substance : Small Molecules The patented CESS technology is based on supercritical CO2. The drug solution is expanded through a controlled process to produce pure drug nanoparticles. In this poster we show our nanonisation approach and a few case studies of nanoparticle production for tuning the particle size of APIs. Keywords: Nanoparticles, nanonisation Niklas Sandler [email protected] View PDF | Demand for Biotech packaging drives significant PCI investment at multiple locations world wide PCI Pharma Services Drug Product : Other PCI recognise that biologically derived therapeutic products are the new frontier, heralding revolutionary treatments of a number of diseases and injuries. We have committed to a $20m investment in support of biologic medicines and advanced injectable delivery forms. Expanding our Biotech clinical and commercial packaging and release testing capability at our Centre of Excellence in Philadelphia, as well as expanded Cold Chain capacity at numerous global locations. Keywords: Biologics, High Potent, development, clinical, manufacturing, packaging, ultra cold chain Joanne Phelps [email protected] View PDF |
| Continuous technology improvement: key partnership to meet your outsourcing needs Procos SpA Drug Substance : Small Molecules Procos S.p.A. is a CDMO focused to the development, scale-up and manufacturing of Active Pharmaceutical Ingredients (API’s) and has continuously expanded its technology portfolio in the last ten years in order to match customer needs. The approaches are mainly through business opportunity and customer partnership. Reported as showcases, the recent expansion into High Potent API to respond to the current market needs and the flow chemistry implementation, requested by an established customer. Keywords: HPAPI, Flow Chemistry, API, Small Molecules Simone Manzini [email protected] View PDF | Digitalisation of Research Outsourcing scientist.com Discovery : Other Digitalisation of business processes and drug development is a trend that will not be going away anytime soon. Scientist.com are supporting the worlds best pharma and Biotech companies to digitalise their research outsourcing processes. Creating faster science by: - Giving science time back to researchers - Removing legal delays - Accessing global innovation Real life case studies and data provide a compelling argument to transform research outsourcing. Keywords: Outsourcing, Digitalisation, Pre-clinical, toxicology, HBS, Human Samples, Faster Science, Protein, Antibodies, Speed, Pharma, Biotech, HEOR, RWE Tom Dexter [email protected] View PDF |
| Diazomethane: embracing hazardous chemistry at scale and through the utilisation of flow technology Sterling Pharma Solutions Ltd Drug Substance : Small Molecules Dr Dan Stark will be presenting Sterling Pharma Solutions capabilities for the scale-up and manufacture of complex and hazardous synthesis. Showcased through Sterling’s current work on diazomethane and the utilisation of modern flow chemistry technologies in API manufacture. Keywords: Diazomethane Dr Dan Stark [email protected] View PDF | Development and Scale up of continuous flow processes for the manufacture of API Thermo Fisher Scientific Drug Substance : Small Molecules Keywords: APi, flow chemistry, continuous process Peter Poechlauer [email protected] View PDF |
Click here to view BOS cmc 2018 poster submissions.